47 results about "Receptor targeting" patented technology

The invention relates to the field of biological medicine, in particular to a hair follicle targeted delivery system and hair growth and hair loss prevention cosmetics, the hair follicle targeted delivery system comprises: a lipid nanoparticle core which is internally loaded with a bioactive component with hair growth and hair loss prevention effects; the hair follicle targeting molecule can specifically recognize and bind to a receptor on the surface of a hair follicle cell; a targeting anchoring conjugate composed of a linker covalently linked to the hair follicle targeting molecule and an anchoring lipid; wherein the targeting anchoring conjugate is embedded into the lipid bilayer of the lipid nanoparticle core through the anchoring lipid, so that the hair follicle targeting molecule is displayed on the surface of the lipid nanoparticle core. According to the application, through an innovative targeted anchoring conjugate structure, the targeting property and enrichment efficiency of hair growth and hair loss prevention active ingredients on hair follicle tissues can be remarkably improved, and the effect that a medicine accurately acts on a focus part is ensured, so that the number of hair follicles at an alopecia areata modeling part can be remarkably increased.

The invention belongs to the technical field of biomedical imaging, and particularly discloses an in-vivo imaging method of an SAPAP3 gene defect disease model, which is characterized in that an effective dose of an S1PR1 receptor targeted radioactive probe is injected into the body of the SAPAP3 gene defect disease model. According to the method, an S1PR1 receptor targeting radioactive probe is utilized, the technical bottleneck that in-vivo and dynamic observation of the S1PR1 receptor cannot be achieved through an existing in-vitro technology is solved, and an indispensable visual tool and a quantitative evaluation means are provided for studying the neurobiological mechanism of related mental diseases such as obsessive-compulsive disorder and accelerating research and development of related drugs.

Methods are provided for attaching a mannose-binding C-type lectin receptor targeting moiety to a polymeric carbohydrate scaffold using an amide bond, which can be found between a leash, such as an amine-terminated leash, and the mannose-binding C-type lectin receptor targeting moiety. The disclosed compounds and compositions utilizing this amide bond provide highly stable compounds that significantly reduce loss of the mannose-binding C-type lectin receptor targeting moiety from the polymeric carbohydrate scaffold.

The application discloses a PROTAC compound with RORgamma t receptor targeted degradation and purposes thereof, which is a compound with a structure shown in a general formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition thereof. e is a ligand capable of combining with an E3 ubiquitin ligase; the L is a linking group covalently combining at least one R e and at least one R W ; the R w is a target protein RORgamma t binding ligand; the application is based on the target point of RORgamma t and the PROTAC technology, and a series of RORgamma t-PROTACs are designed and synthesized for the first time. The mechanism is that the target protein ligand and the E3 ubiquitin ligase ligand are combined with POI and E3 ligase respectively, so as to form a ternary complex of "POI-PROTAC-E3 ligase". Then, the POI is marked with a ubiquitination label, and is degraded by a proteasome. The advantages of RORgamma t-PROTACs mainly include targeting of "undruggable proteins", small dosage, low toxicity, and difficulty in drug resistance. W -L-R e (I)

This invention relates to the field of biomedicine, and more particularly to a hair follicle-targeted delivery system and a hair growth and anti-hair loss cosmetic. The hair follicle-targeted delivery system comprises: a lipid nanoparticle core loaded with bioactive ingredients having hair growth and anti-hair loss effects; a hair follicle-targeting molecule capable of specifically recognizing and binding to receptors on the surface of hair follicle cells; and a targeting and anchoring conjugate consisting of a linker covalently linked to the hair follicle-targeting molecule and an anchoring lipid. The targeting and anchoring conjugate is embedded in the lipid bilayer of the lipid nanoparticle core via the anchoring lipid, thereby exposing the hair follicle-targeting molecule on the surface of the lipid nanoparticle core. This application, through its innovative targeting and anchoring conjugate structure, can significantly improve the targeting and enrichment efficiency of the hair growth and anti-hair loss active ingredients on hair follicle tissue, ensuring precise drug action on the lesion site, thereby significantly increasing the number of hair follicles in the alopecia areata modeling area.

The invention discloses a lipidosome composite hydrogel microsphere for repairing damaged intestinal mucosa and a preparation method thereof, LHMs (at) 4-OI is composed of hyaluronic acid modified targeted drug-loaded lipidosome, sodium alginate, hydrochloric acid treated sucralfate and a CaCl cross-linking agent, and rapid gel forming is carried out under the voltage of 11.0 KV through an electrospray technology. The microspheres have pH responsiveness and gastric juice digestion resistance, CD44 receptor targeting is achieved through hyaluronic acid modification, sodium alginate and Ca form an egg box structure to provide a three-dimensional network, and sucralfate enhances adhesion to isolate harmful substances. The preparation method comprises the steps of preparation of the drug-loaded liposome by a film hydration method, hyaluronic acid modification and electrospray crosslinking, is simple to operate and low in cost, and can be used for large-scale production. The microspheres can effectively load an anti-inflammatory drug 4-OI, inhibit expression of inflammatory factors and promote self-repair of damaged intestinal mucosa, and have wide application prospects in the fields of abdominal infection, inflammatory bowel diseases, colorectal cancer and the like.

The invention discloses a functionalized targeting fluorescent nanoprobe and application thereof in protein mutation analysis, and relates to the technical field of biology, the fluorescent nanoprobe comprises a targeting molecule-PEG hydrophilic bridging molecule and a matrix; the preparation method comprises the following steps: adding nano-seeds into fluorescent molecules to prepare fluorescent nano-particles, and stirring and mixing the fluorescent nano-particles with targeting molecules-PEG hydrophilic bridging molecules; the method is combined with deep learning to be applied to protein mutation analysis. The multifunctional integrated protein mutation receptor targeted fluorescent nanoprobe provided by the invention can accurately mark the position of a mutant protein at a single cell level, and can realize in-situ, real-time and dynamic living cell imaging of a tumor cell endogenous molecular mutant protein; and qualitative and quantitative analysis of tumor cell protein mutation can be realized through subcellular localization of the targeted fluorescent nanoprobe.

The application provides a folate receptor targeted drug, a metal complex and a preparation method and application thereof, and relates to the technical field of radio labeling. The folate receptor targeted drug has a structure as shown in formula I, and a metal complex is prepared after being labeled by a radionuclide. The folate receptor targeted drug or the metal complex provided by the application can be used for diagnosing and / or treating diseases with overexpression of folate receptors. The folate receptor targeted drug has the advantages of high in-vivo stability, strong specificity, good targeting property and the like.

Provided are methods of treating myelodysplastic syndrome (MDS), oligoblastic acute myelogenous leukemia (O-AML), or chronic myelomonocytic leukemia (CMML) using 765IGF-MTX and other IGF-receptor-targeted agents, and formulations for delivering 765IGF-MTX and other IGF-receptor-targeted agents to patients. Also provided are pharmaceutical compositions for use in treating MDS, O-AML, and CMML.

Provided are a multifunctional genetically modified immune cell, and a preparation method and use therefor. The multifunctional gene modification vector carries an isolated nucleic acid. The isolated nucleic acid comprises: a first nucleic acid fragment, a second nucleic acid fragment and a third nucleic acid fragment. The first nucleic acid fragment, the second nucleic acid fragment and the third nucleic acid fragment are connected. The first nucleic acid fragment is used for encoding an antigen chimeric receptor targeting a NKp30 ligand. The second nucleic acid fragment is used for encoding a fusion protein, wherein the fusion protein comprises IL-15 and IL-15 Rα, and IL-15 is connected to IL-15 Rα. The third nucleic acid fragment is used for encoding a CXCR2 receptor. Therefore, the multifunctional genetically modified immune cell prepared by using the multifunctional gene modification vector can improve the specific killing ability, survival ability, proliferation ability and tumor infiltration ability of the immune cell, so that the clinical curative effect of the immune cell is further improved.

This application discloses a compound or a pharmaceutically acceptable salt thereof, said compound comprising a compound of formula (I) or a compound of formula (II). A radioactive element preparation comprising thereof and a radioactive element chelated therewith is also disclosed. Its use in the preparation of reagents targeting CXCR4, particularly CXCR4 tracers, more particularly in vivo CXCR4 tracers, or reagents that specifically bind to cells expressing CXCR4 is also disclosed. [Targeting Peptide-I]-Xaa1-X 1 (R 1 )L 1 -[Connector]-R x n1 (I), R x n1 -[Connector]-X 1 (R 1 )L 1 -Xaa1-[targeting peptide-II](II).

The present application relates to the technical fields of biological medicine and cellular immunotherapy, and particularly relates to a signal conversion receptor targeting IL-10, an engineered macrophage and application thereof. The signal conversion receptor is composed of an extracellular domain and a transmembrane domain and an intracellular domain derived from TLR9, and the extracellular domain sequentially comprises a signal peptide, a HA tag and a specific binding domain of an IL-10 receptor alpha subunit from N-terminal to C-terminal. The present application further prepares an engineered macrophage SR CAR-M capable of specifically recognizing IL-10 and converting it into a TLR9 activation signal, which can induce macrophages to polarize to M1 type and has excellent phagocytosis and killing capacity for bladder cancer, breast cancer, lung cancer and melanoma cells, and can be used for preparing related tumor treatment drugs, overcoming the common problems of existing cell therapy, such as easy exhaustion, difficult infiltration and easy inhibition in solid tumors, and having significant clinical transformation potential.

The invention provides a GSH (glutathione) reduction response type targeted nano-drug based on chondroitin sulfate as well as a preparation method and application of the GSH reduction response type targeted nano-drug. Chondroitin sulfate with CD44 receptor targeting ability and an anti-cancer drug camptothecin are covalently linked through a disulfide bond sensitive to GSH, and the constructed novel targeting nano-drug can accurately recognize human colorectal cancer tumor cells highly expressed by a CD44 receptor in a targeting manner. Meanwhile, the high-concentration glutathione at the tumor site can oxidize and reduce the disulfide bond to cause the fracture of AC-CPT NPs, so that the effective release of the camptothecin medicine at the tumor site is realized, and the anti-tumor effect is further enhanced. The reduction response type targeting nano-drug prepared by the invention solves the problems of poor targeting and biological solubility and limited treatment effect of the traditional anti-cancer drug camptothecin, and provides an innovative strategy for realizing accurate targeting and efficient treatment of cancers.

This invention discloses a folic acid receptor-targeting compound and its uses, belonging to the field of pharmaceutical technology. The folic acid receptor-targeting compound is a compound of formula (I), its stereoisomer, its crystalline hydrate, its deuterated derivative, its solvate, its prodrug, or a pharmaceutically acceptable salt thereof: [target]-(L x ) s -R x (I), where [target] is a folic acid receptor-binding ligand; R x The chelating group is Ch or the prosthetic group is PG; s is an integer from 1 to 10; L x It contains at least one L 3 and with AA, L 1 L 2 or L 3 Arbitrary combinations are possible. The folic acid receptor-targeting compounds of this invention have low KD values ​​and strong affinity between the ligands and receptors, and can be used as folic acid receptor-targeted radiotherapy agents for imaging, diagnosis, and treatment of folic acid receptor (FR)-expressing tumors or cells.

The invention belongs to the technical field of medicines, and discloses a paclitaxel and silver nanoparticle loaded lipidosome nano-targeting preparation as well as preparation and application of the paclitaxel and silver nanoparticle loaded lipidosome nano-targeting preparation. According to the invention, nano-particles coated with silver nano-particles are prepared by adopting a film dispersion method. The nano-drug provided by the invention is helpful for solving the problems of poor water solubility, low bioavailability, poor tumor targeting property, strong toxic and side effects and the like of an anti-cancer drug paclitaxel and low bacterial uptake efficiency of an antibacterial drug Ag Nps, and provides a hyaluronic acid coated CD44 receptor targeted paclitaxel and Ag Nps co-loaded liposome nano-targeting preparation, so that the anti-tumor effect is improved. The preparation process is simple, the cost is low, the stability is good, and the repeatability is high.

The invention belongs to the technical field of gene engineering, and provides Hsp60 receptor targeted recombinant lactobacillus plantarum as well as a construction method and application thereof, lactobacillus plantarum is taken as a host, pPG612 is taken as an expression vector, and CsgB gene or CsgF gene is expressed. The two engineering probiotics can express target protein and can be stably expressed on the surfaces of thalli, the AB.9 intestinal epithelial cells can be effectively adhered, and the adhesion and invasion of the A.veronii to the AB.9 cells can be inhibited. And secondly, the engineering probiotics LP-pPG-CsgB and LP-pPG-CsgF can promote the proliferation of dendritic cells, T lymphocytes and B lymphocytes, and improve the IgT secretion of intestinal mucus. The engineering bacteria can be competitively combined with an intestinal epithelial cell Hsp60 receptor, down-regulate p65 expression, inhibit NF-kappa B signal channel activation, regulate intestinal tight junction protein redistribution and down-regulate proinflammatory factor expression through a TLR4 / TLR5 dependent NF-kappa B signal channel, and the engineering bacteria can increase the abundance of effective microbial communities in the intestinal tract of the snakeheaded fish, so that the growth of the snakeheaded fish is promoted, and the growth of the snakeheaded fish is promoted. And the flora can transfer, mediate and activate immune response through a feeding environment.

The invention discloses a cell membrane bionic magnetic nano-microsphere based on cannabinoid receptor CB2 receptor targeting, a preparation method of the cell membrane bionic magnetic nano-microsphere and application of the cell membrane bionic magnetic nano-microsphere to analgesic screening. The cell membrane bionic magnetic nano-microsphere takes a surface aldehyde group modified magnetic nano-microsphere as a core; a cell membrane of a high-expression cannabinoid receptor CB2 is wrapped on the surface of a magnetic bead by using a covalent bond binding method, a potential agonist is screened based on ligand-receptor affinity interaction, the active ligand of the cannabinoid receptor CB2 is efficiently captured by using a bionic magnetic nano material fishing technology, active components can be rapidly and sensitively screened out, and the application prospect is wide. The method is simple in operation, reduces analysis steps and time, improves analysis accuracy, remarkably improves separation efficiency and specificity of trace active components in a complex system by adopting collaborative innovation of a magnetic nano material and a biomimetic membrane technology, and has a great application prospect.

The invention provides a chimeric autoantibody receptor of a targeted acetylcholine receptor antibody, a CAAR-T cell and application of the chimeric autoantibody receptor in a medicine for preventing and treating myasthenia gravis, and belongs to the technical field of biological medicines. The invention provides a chimeric autoantibody receptor (CAAR) targeting an acetylcholine receptor antibody, which is characterized in that three extracellular domains of an AChR alpha subunit are connected in series through L1 and L2 connecting peptides or G4S connecting peptides to form an extracellular domain, and meanwhile, CD3 gamma only containing an ITAM motif is used as a signal transduction domain. The CAAR is expressed on the surface of a T cell, and the obtained CAAR-T not only has relatively strong binding capacity with an anti-AChR antibody, shows a relatively strong killing effect on pathogenic B cells expressing the anti-AChR antibody, can effectively relieve the symptom of myasthenia gravis, but also has relatively low risk of inducing cytokine storm, and has good drug safety.

This invention discloses the application of GRP94 protein as a drug delivery target in the construction of drug carriers for Parkinson's disease. GRP94 is highly upregulated on the cell membranes of dopaminergic neurons in the substantia nigra of Parkinson's disease cells, while its expression is extremely low on the surface of normal brain cells. The invention also discloses the application of GRP94 as a target in a targeted delivery system for anti-Parkinson's disease drugs. By targeting GRP94, the delivered anti-Parkinson's drug can efficiently penetrate the blood-brain barrier to reach the brain parenchyma, avoiding normal brain cells and specifically targeting dopaminergic neurons in the substantia nigra of Parkinson's disease cells, thus achieving targeted drug delivery for Parkinson's disease. This invention applies GRP94 as a target in the construction of drug carriers for Parkinson's disease and in the preparation of targeted delivery systems for anti-Parkinson's disease drugs. Compared to other target receptors that cross the blood-brain barrier for targeted brain delivery, targeting GRP94 more specifically targets dopaminergic neurons in the substantia nigra, avoiding drug accumulation and neurotoxicity in normal intracranial regions.

The invention relates to an extraction process for targeted induction of a TGF-beta and IL-10 anti-inflammatory factor combination secreted by mesenchymal stem cells and application of the TGF-beta and IL-10 anti-inflammatory factor combination in a pain treatment preparation, according to the process, the mesenchymal stem cells are specifically activated through VEGF-A-link-TNF-alpha fusion protein as shown in SEQ ID NO: 4, and the secretion level of TGF-beta and IL-10 of the mesenchymal stem cells is remarkably improved; the fusion protein is cooperated with a TNF-alpha inflammation signal through a VEGF receptor targeting effect, so that efficient induction of anti-inflammatory factor expression is realized; the mesenchymal stem cells pretreated by the VEGF-A-link-TNF-alpha fusion protein as shown in SEQ ID NO: 4 can remarkably relieve the pain hypersensitivity of a neuropathic pain model, and have a remarkable clinical application prospect.

Subject matter of the present invention is a lyophilized kit formulation for the preparation of radiometal labeled chelate-functionalized GRP receptor targeting conjugates comprisinga chelate-functionalized GRP receptor targeting conjugate comprisingi. a chelating moietyii. at least one targeting moiety, wherein said targeting moiety is a GRP receptor (GRPr) targeting peptide, andiii. optionally, at least one linker, connecting the chelating moiety with the GRP receptor (GRPr) targeting moiety, andat least one GRP receptor (GRPr) targeting moiety,at least one non-reducing sugar selected from the group comprising trehalose and sucrose, andat least one radio stabilizer, selected from the group comprising ascorbic acid, ascorbic acid salts, gentisic acid, gentisic acid salts, or mixtures thereof.

The present invention discloses compounds of Formula (I) and their complexes with radionuclides that can recognize both Somatostatin type 2 receptor (SSTR2) and cholecystokinin 2 receptor (CCK2R) and can be used in the diagnosis and treatment of diseases where either or both receptors are overexpressed.

Disclosed are compositions, methods, and systems for imaging disease states using near-infrared fluorescent dyes conjugated to receptor-targeted molecules. In some aspects, a method for preparing an imaging agent includes covalently attaching a zwitterionic near-infrared fluorophore to a molecule containing a primary amino group, wherein the fluorophore comprises a sulfo-phenoxy substituent at the central methine carbon and sulfonic acid substituents at the 5-position of the indole nucleus. In some embodiments, the sulfo-phenoxy substituent imparts enhanced chemical stability to the dye, while the sulfonic acid substituents enable precise tuning of absorbance and emission maxima to desired near-infrared wavelengths. These features collectively facilitate the development of imaging agents with improved photostability, spectral properties, and conjugation efficiency for use in biomedical research and clinical diagnostics.

Genetically modified cells (e.g., recombinant mammalian cells) and methods for improving the expression / functional response of olfactory receptors are described herein. Genetically modified cells and methods can generally modulate the levels of chaperone proteins that help target receptors to the cell membrane. Genetically modified cells and methods can also provide a platform for use in studying the function of a broader group of chemosensory receptors, including taste receptors and TRP channels.

The application relates to an integrin receptor targeting polypeptide derivative and molecular probe and application. The integrin receptor targeting polypeptide derivative has a structure shown in formula I. The novel polypeptide derivative constructed by the application has the function of simultaneously coupling multiple imaging molecules, and can be simultaneously used for preoperative diagnosis and intraoperative guidance of multiple imaging methods. The research result can provide a new idea for further development of molecular imaging, and increase the range of clinical application of molecular imaging.

The application belongs to the technical field of genetic engineering, and provides Hsp60 receptor targeted recombinant plant lactobacillus, a construction method and application. The plant lactobacillus is used as a host, pPG612 is used as an expression vector, and CsgB genes or CsgF genes are expressed. Two strains of engineering probiotics can express target proteins and can stably express on the surface of the bacterial body, effectively adhere to AB.9 intestinal epithelial cells, and can inhibit the adhesion and invasion of AB.9 cells. A. veronii Secondly, the engineering probiotics LP-pPG-CsgB and LP-pPG-CsgF can promote the proliferation of dendritic cells, T lymphocytes and B lymphocytes, and improve the secretion of intestinal mucus IgT. The engineering bacteria can also competitively bind to the Hsp60 receptor of intestinal epithelial cells, down-regulate the expression of p65 through the TLR4 / TLR5 dependent NF-κB signal pathway, inhibit the activation of the NF-κB signal pathway, regulate the redistribution of intestinal tight junction proteins, and down-regulate the expression of pro-inflammatory factors. Furthermore, the engineering bacteria can increase the abundance of intestinal beneficial flora of the snakehead, and the flora can mediate and activate the immune response through the feeding environment.

The invention relates to the technical field of tumor treatment, and discloses a polymeric drug-loaded particle servo type controlled release system and method based on high-frequency oscillation excitation. The system comprises polymeric drug-loaded particles; the Doppler echo repositioning module is used for acquiring imaging information of the tumor tissue in real time and generating a servo-adjusted sound signal according to the imaging information; the array type ultrasonic unit is in communication connection with the Doppler echo re-positioning module and is used for receiving the sound signal subjected to servo adjustment and transmitting high-frequency ultrasound according to the sound signal; wherein when the high-frequency ultrasound acts on the polymeric drug-loaded particles, the polymeric drug-loaded particles are positioned on target tissues under the dual effects of tumor cell surface receptor targeting and subcellular structure targeting, and the sound-sensitive agent generates active oxygen under the excitation of the high-frequency ultrasound, so that the drug-loaded particles can be used for treating tumor cells. And the array type ultrasonic unit can adjust the ultrasonic excitation intensity in real time according to the imaging of the tumor tissue so as to realize the instantaneous active oxygen filling of the target tissue and reconstruct the tumor microenvironment.

The present application provides a near-infrared two-region AIE probe and a nano material for light-activated treatment of bladder cancer, and belongs to the technical field of material chemistry. In view of the poor treatment effect of photothermal therapy on bladder cancer, the present application designs an AIE probe capable of efficient photo-thermal conversion in the near-infrared two-region, and on the basis of the AIE probe, the AIE probe is blended with a heat-sensitive NO donor to release NO through near-infrared light-induced photo-thermal conversion. After being encapsulated by an amphiphilic polymer, the surface of the cell membrane is modified with PMCA calcium ion channel blocking peptides and tumor surface FGFR1 receptor targeting peptides. The PMCA calcium ion channel blocking peptides on the surface of the cell membrane and the NO released by the heat-sensitive NO donor jointly act on the calcium ion channel through endogenous and exogenous combined regulation, causing calcium overload in the tumor and inducing tumor cell apoptosis. The tumor surface FGFR1 receptor targeting peptides on the surface of the cell membrane can realize efficient enrichment of the nano material at the tumor site, thereby improving the treatment effect. The material provided by the present application provides a new idea for the treatment of bladder cancer.

The present invention provides a chimeric antigen-receptor targeting LRRC15, which exhibits drug efficacy against tumors associated with LRRC15 positive cells, and cells comprising the same.SOLUTION: To provide a chimeric antigen-binding receptor containing an anti- LRRC15 antigen-binding site containing a specific CDR, and to provide chimeric antigen-binding receptor-expressing cells containing the receptor.SELECTED DRAWING: None